Journal Article

A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study

Zhang, Hui, Zhang, Zhiyuan, Zhang, Wenming, Zhou, Menglong, He, Yiping, Zhou, Changming, Wang, Yan, Zhang, Jing, Sheng, Weiqi, Xuan, Yan, Tan, Cong, Xia, Fan, Li, Guichao, Wang, Yaqi, Huang, Hua, Yang, Wang, Zhang, Zhaozhen, Zou, Wei, Zhang, Zhen, Mo, Miao, Wan, Juefeng, Li, Huanhuan, Liu, Yuan, Zhu, Hui, Liu, Xiaowen, Weng, Weiwei, Wang, Lei, Wang, Yanong, Huang, Dan, Shen, Lijun

2022

Overview

Background Perioperative chemotherapy (ChT) and preoperative chemoradiation (CRT) are both the standard treatments for locally advanced gastric cancer (LAGC). CRT can achieve a higher pathological complete regression (pCR) rate, but whether this higher pCR rate can be transformed into a long-term survival benefit remains inconclusive. Therefore, relevant studies are in progress. On the other hand, immunotherapy has been established for the first-line treatment of advanced gastric cancer (AGC) and has been widely explored in the perioperative setting. The combination of chemotherapy/radiotherapy and immunotherapy may have a synergistic effect, which will lead to a better antitumor effect. The preliminary reports of ongoing studies show promising results, including a further improved pCR rate. However, the preferred treatment combination for LAGC is still not established. To solve this problem, we are carrying out this randomized phase II trial, which aims to evaluate the efficacy and safety of perioperative chemotherapy plus the use of PD-1 antibody with or without preoperative chemoradiation for LAGC. Methods Eligible patients with LAGC or gastroesophageal junction (GEJ) adenocarcinoma were randomized to receive perioperative ChT, PD-1 antibody, surgery with (Arm A) or without preoperative CRT (Arm B), and PD-1 antibody maintenance until one year after surgery. The primary endpoint of this study is that the pCR rate of Arm A will be significantly higher than that of Arm B. The secondary endpoints include the pathological partial regression (pPR) rate, R0 resection rate, objective response rate (ORR), event-free survival (EFS), overall survival (OS), safety and surgical complications. Moreover, several explorative endpoints will be evaluated to find and validate the predictive biomarkers of immunotherapy. Discussion The results of the NeoRacing study will provide important information concerning the application of PD-1 antibody in LAGC patients during the perioperative setting. Meanwhile, the two treatment protocols will be compared in terms of efficacy and safety. Trial registration ClinicalTrials.gov , NCT05161572 . Registered 17 December 2021 - Retrospectively registered.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adenocarcinoma / Adenocarcinoma - pathology / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antitumor activity / Biomedical and Life Sciences / Biomedicine / Cancer / Cancer Research / Cancer therapies / Care and treatment / Chemoradiotherapy / Chemotherapy / Clinical medicine / Clinical trials / Clinical Trials, Phase II as Topic / Comparative analysis / Enrollments / Esophageal cancer / Esophageal Neoplasms / Esophagogastric Junction - pathology / Gastrectomy / Gastric cancer / Gastroesophageal junction adenocarcinoma / Health Promotion and Disease Prevention / Humans / Immunotherapy / Immunotherapy - adverse effects / Locally advanced gastric cancer / Medical prognosis / Medicine/Public Health / Metastasis / Methods / Monoclonal antibodies / Oncology / Patients / PD-1 protein / Perioperative care / Preoperative chemoradiation / Programmed Cell Death 1 Receptor - therapeutic use / Radiation therapy / Radiotherapy / Randomized Controlled Trials as Topic / Response rates / Safety / Stomach Neoplasms - pathology / Study Protocol / Surgery / Surgical Oncology / Surgical outcomes / Survival